COMMUNIQUÉS West-GlobeNewswire

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
30/10/2026
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios’ response to the information request as a major amendment to the mitapivat [...]
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
30/10/2026
Patent milestones build on positive REMAIN-1 six-month pivotal results and patient research supporting interest in a one-time procedure for post-GLP-1 weight maintenance New catheter patent provides protection extending [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
30/10/2026
Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA [...]
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
30/10/2026
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months [...]
Syndax Announces Participation in November Investor Conferences
30/10/2026
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
30/10/2026
Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending [...]
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion Protein
30/10/2026
Dual-Target Approach Designed to Modulate Both Innate and Adaptive Immunity Advances Into Clinical Evaluation in Patients With SLE NANJING, China, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (" [...]
Nicox publie les résultats financiers du premier semestre 2026
30/10/2026
Communiqué de presse Nicox publie les résultats financiers du premier semestre 2026 Chiffre d’affaires de 3,5 millions d’euros contre 1,5 million d’euros au premier semestre 2025 Perte nette réduite à 0,5 million d’ [...]
Nicox Reports First Half 2026 Financial Results
30/10/2026
Press Release Nicox Reports First Half 2026 Financial Results Revenue increased to €3.5 million compared to €1.5 million in H1 2025 Net loss decreased to €0.5 million from €8.9 million in H1 2025 Cash and cash [...]
Communiqué de presse : T3 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA ; révision à la hausse des perspectives 2026
30/10/2026
T3 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA ; révision à la hausse des perspectives 2026 Paris, le 30 octobre 2026 Ventes du T3 en progression de 14,3 % à TCC 1 et BNPA 2 des activités de 3,55 [...]
Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded
30/10/2026
Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER 1 and business earnings per share (EPS) 2 of €3.55 Pharma launches sales increased by 31 [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026
30/10/2026
Tokyo, Japan and Cambridge, UK, 30 October 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter ended 30 [...]
Fangzhou Honored with Digital Intelligence Leadership Award at Tencent Summit, Expands Healthcare AI Partnership with Tencent Health
30/10/2026
SHANGHAI, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, received the “Digital-intelligence Leadership Award- [...]
Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026
30/10/2026
Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026 Halle (Saale) / Munich, Germany, October 30, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a [...]
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
30/10/2026
This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX [...]
2026 InLight Foundation Stanford Frontier Dialogue: From Nobel Optogenetics to Mind-Light Contemplation, Cross-Disciplinary Experts Explore New Frontiers in Consciousness Regulation
30/10/2026
PALO ALTO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Following the awarding of the 2026 Nobel Prize in Physiology or Medicine to pioneers in optogenetics, the InLight Foundation concluded its "Consciousness and Science [...]
InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China
30/10/2026
BEIJING, Oct. 30, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum